Quantcast

Global Radiopharmaceuticals Industry

September 24, 2013

Reportbuyer.com just published a new market research report:
Global Radiopharmaceuticals Industry.

London (PRWEB) September 24, 2013

This report analyzes the worldwide markets for Radiopharmaceuticals in US$ Million by the following Product Segments: Diagnostic Radiopharmaceuticals, and Therapeutic Radiopharmaceuticals.

The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East, and Latin America.

Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets.

The report profiles 69 companies including many key and niche players such as Actinium Pharmaceuticals, Inc., Advanced Medical Isotope Corporation, Alseres Pharmaceuticals, Inc., Bayer HealthCare Pharmaceuticals, Bracco Diagnostics, Inc., Cardinal Health, Inc., Covidien Plc, Eli Lilly and Company, Erigal Limited, EUSA Pharma (Europe) Ltd., GE Healthcare, IBA Group, Immunomedics, Inc., Jubilant Life Sciences Limited, Lantheus Medical Imaging Inc., Medi-Radiopharma Ltd., Nordion Inc., Peregrine Pharmaceuticals, Inc., PETNET Solutions Inc., Positron Corporation, Singapore Radiopharmaceuticals Pte Ltd., and Triad Isotopes, Inc.

Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs.

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1

Disclaimers I-2

Data interpretation & Reporting Level I-2

Quantitative Techniques & Analytics I-3

Product Definitions and Scope of Study I-3

A. Diagnostic Radiopharmaceuticals I-3

B. Therapeutic Radiopharmaceuticals I-4

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW II-1

A Quick Primer II-1

Market Scenario: Recession and the Road Ahead II-1

Recession: A Period of Global Decline II-1

The Road to Recovery II-2

Outlook II-2

Impact of Healthcare Budget Cuts in Developed Economies: A Review II-3

Diagnostic Radiopharmaceuticals: The Dominant Segment II-4

Promising Developments in Therapeutic Radiopharmaceuticals

Underway II-4

2. GROWTH DRIVERS & TRENDS II-6

New Therapeutic Radiopharmaceuticals to Drive Global Market II-6

Improvements in Imaging Technology II-6

Rise in International Investments for Radiopharmaceuticals II-6

Bayer Algeta Partnership for Alpharadin II-6

Lutathera II-7

AREVA Med II-7

AtlabPharma and Cornell Well Medical Center II-7

Zevalin’s Landmark FDA Approval Offers New Opportunities II-7

Improved Reimbursement for Therapeutic Radiopharmaceuticals II-7

Rise in Cancer Incidences & Access to Modern Therapeutics

Foster Growth II-8

World Cancer Statistics – Incidence and Mortality Data II-9

Table 1: World Cancer Incidence by Geographic Region and Gender (2012): Number of New Cancer Cases Reported in Thousands for Asia-Oceania, Europe, North America, Latin America & the Caribbean, and Africa (includes corresponding Graph/Chart) II-9

Table 2: World Cancer Mortality by Geographic Region and Gender (2012): Number of Cancer- Related Deaths in Thousands for Asia-Oceania, Europe, North America, Latin America & the Caribbean, and Africa (includes corresponding Graph/Chart) II-10

Table 3: Global Incidence of Common Cancers in Men (2012): Number of New Cases Reported in Thousands for Lung & Bronchus, Prostate, Colorectal and Liver Cancers (includes corresponding Graph/Chart) II-10

Table 4: Global Incidence of Common Cancers in Women (2012): Number of New Cases Reported in Thousands for Breast, Colorectal, Lung & Bronchus and Liver Cancers (includes corresponding Graph/Chart) II-11

Table 5: Global Cancer Mortality in Men for Select Cancers (2012): Number of Deaths in Thousands for Lung & Bronchus, Liver, Colorectal and Prostate Cancers (includes corresponding Graph/Chart) II-11

Table 6: Global Cancer Mortality in Women for Select Cancers (2012): Number of Deaths in Thousands for Breast, Lung & Bronchus, Colorectal and Liver (includes corresponding Graph/Chart) II-11

Table 7: World Breast Cancer Statistics: Top 20 Countries with Highest Breast Cancer Rates (includes corresponding Graph/Chart) II-12

Cancer Prone Sites based on Age II-12

Targeted Radionuclide Therapy: Gaining Ground in Cancer Treatment II-13

Intra-operative Lymphatic Mapping (ILM): Creating New Opportunities for Radiopharmaceuticals in Cancer Detection II-13

Emergence of Radioisotope Based Personalized Therapy Bodes Well for the Market II-13

Recognition of Intrinsic Cost Benefits: Critical to Market Acceptance II-14

Widespread Awareness among Practitioners & Patients: The Need of the Hour II-14

Cardiology: An Important Sector for Radiopharmaceuticals II-14

Expansion of Molecular Imaging Platform is Key to Future Growth II-15

Battling Alzheimer’s Disease – A Powerful Market Force II-15

Table 8: Elderly Population (65+ Years) as a Percentage of the Total Population: 2000 & 2025 (includes corresponding Graph/Chart) II-16

Growing Demand for PET to Drive up Demand II-17

Opportunities Increasing for Fluorine-Based Myocardial Perfusion Agents II-17

Innovative PET Biomarkers in the Offing for Oncology II-17

Hypoxia Imaging Presents Opportunities for PET II-18

Introduction of SPECT/CT & PET/CT: Double Edged Weapons for Growth II-18

Targeted Peptides & Alpha Emitters: The New Frontiers of Therapeutic Radiopharmaceuticals II-19

International Collaborations Give a Thumbs Up to Drug Development II-19

Key Statistical Data II-20

Table 9: Worldwide Market for 99Mo (2010): Percentage Share Breakdown of Weekly Demand by Region (includes corresponding Graph/Chart) II-20

Table 10: Worldwide Market for 99Mo (2010): Percentage Share Breakdown of Production by Reactor (includes corresponding Graph/Chart) II-20

Reactors Producing Cobalt 60 & Molybdenum 99 II-21

Table 11: Global Projected Demand for Mo-99 in Emerging and Mature Markets for the Years 2020 and 2030 (includes corresponding Graph/Chart) II-21

3. MARKET CHALLENGES II-22

High Costs of Drug Development Piques Manufacturers II-22

Supply Shortages: A Niggling Cause of Concern II-22

Canadian Scientists Discover Means to Address Supply Shortages II-23

Price Sensitivity & Competition from Alternatives Limit Market Potential II-23

Lack of Dosage Standards for Pediatric Patients Limits Radiopharmaceutical Efficacy II-24

Unfounded Fears of Radiation Exposure Hinder Growth II-24

Bottlenecks in Developing Markets II-24

4. THERAPEUTIC RADIOPHARMACEUTICAL PRODUCTS UNDER DEVELOPMENT II-25

Primer II-25

Lutathera for Neuroendocrine Cancer II-25

Alpharadin for Bone Cancer Treatment II-25

Actimab for Leukemia and Blood Borne Cancers II-25

Lead-212 Alpha Therapy for Metastasized Abdominal Cancers II-26

Lu-177-J591 PSMA Antibody for Prostate Cancer II-26

Indium-111-Pentetreotide for Neuroendocrine Tumors II-26

Yttrium-90 Clivatuzumab for Pancreatic Cancer II-27

CycloSam for Bone Cancer II-27

Phospholid Ether Tumor Targeting II-27

5. IMAGING AGENTS – AN OVERVIEW II-28

A Quick Primer II-28

Growth Drivers II-28

Market Restraints II-29

Significance of Technological Advancements II-29

X-Ray Contrast Media: Giving Way to Emerging Modalities II-29

Medical Reimbursement: A Critical Factor II-30

Market Structure II-30

Select Players by Segment II-30

6. NUCLEAR MEDICINE – AN OVERVIEW II-31

Nuclear Medicine – An Introduction II-31

Growth Drivers in a Nutshell II-31

Market Shifts to Hybrid Imaging II-31

7. PRODUCT OVERVIEW II-33

Radiopharmaceuticals: A Definition II-33

Mechanism of Action II-33

Application of Radiopharmaceuticals II-33

Radioactive Tracers for Diagnostic Imaging II-33

Therapeutics II-33

Research II-34

Sterilization II-34

Classification of Radiopharmaceuticals II-34

Diagnostic Radiopharmaceuticals II-34

Commonly Used Diagnostic Radiopharmaceutical Agents II-34

Major Isotopes and their Diagnostic Applications II-35

Advantages II-36

Classification II-36

Cardiology Diagnostics II-36

Non-cardiology Diagnostics II-36

Molecular Imaging Modalities in Radiopharmaceutical Diagnostics II-36

Planar Imaging II-36

Positron Emission Tomography (PET) II-37

Advantages II-37

Applications of PET II-38

Commonly used Radioisotopes in PET Scans II-38

Major PET Isotopes and their Applications II-38

Single Photon Emission Computed Tomography (SPECT) II-39

Applications of SPECT II-40

Commonly used Radioisotopes in SPECT Scans II-40

Therapeutic Radiopharmaceuticals II-40

Characteristics of Therapeutic Radiopharmaceuticals II-40

Commonly used Therapeutic Agents II-41

Major Isotopes and their Therapeutic Applications II-41

Radiopharmaceuticals for Thyroid Therapy II-41

Radiopharmaceuticals for Cancer Therapy II-42

Radiopharmaceuticals for Neuroendocrine Tumors II-42

Radiopharmaceuticals for Radiosynoviorthesis Therapy II-42

Radiopharmaceuticals for Bone Pain Palliation Therapy II-42

Radiopharmacy: A Key Link in the Distribution Chain II-43

Table 12: US Radiopharmacies Market (2010): Percentage Share Breakdown of SPECT Doses Sold by Company (includes corresponding Graph/Chart) II-43

8. PRODUCT INNOVATIONS/INTRODUCTIONS II-44

Positron Launches Advanced PosiRx Pharmacy Automation Systems II-44

BARC Launches Indigenous Radiopharmaceuticals- Powered Scans II-44

Rapidscan Pharma Solutions EU and GE Healthcare Unveil Rapiscan® II-44

Positron Launches PosiRx II-45

9. PRODUCT INNOVATIONS/INTRODUCTIONS IN RECENT PAST- A PERSPECTIVE

BUILDER II-46

GE Healthcare Enhances Radiopharmaceuticals Product Portfolio II-46

IBA Molecular Obtains Positive Opinion to Market Dopacis in

Europe II-46

BARC Develops Radiopharmaceuticals for Cancer Treatment II-47

Medrad Mounts Intego™ PET Infusion System at UPMC II-47

IBA Molecular Announces the Launch of Cyclone ® 18 Twin II-47

Molecular Insight Develops New Radio-iodinated Molecules II-47

Immunomedics Develops New Antibody for Radio-immunotherapy II-48

10. RECENT INDUSTRY ACTIVITY II-49

Advanced Accelerator Applications Expands Radiopharmaceutical Manufacturing Network II-49

Advanced Accelerator Applications Inks Partnership Agreement with Uwrc Spoka Z Ograniczon Odpowiedzialno Ci II-49

Eli Lilly to Purchase Two Radiopharmaceutical Imaging Agents from Siemens II-49

UPPI Inks Contract with Novation II-50

Dalton Inks Manufacturing Partnership with Clarity Pharmaceuticals II-50

Lantheus Medical Imaging Extends Agreement with Nordion II-50

Lantheus Medical Imaging and Jubilant HollisterStier Enter into Agreement II-51

NCM Reveals New Advanced PET Radiopharmaceutical Manufacturing Center II-51

Turkey Inaugurates First Particle Accelerator II-51

SK Capital and IBA Sign Agreement to Setup IBA Molecular Imaging II-52

Novelos Therapeutics Pockets Cellectar Inc II-52

Southern Research Institute Inks Agreement with Biomedical Research Foundation II-52

IBA Acquires Minority Stake in PET Net Solutions II-53

Amerinet Inks Group Purchasing Agreement with Positron II-53

Premier Purchasing Partners Awards Supplier Contract to Lantheus Medical Imaging II-54

MDS Nordion Inks Collaborative Agreement with Avid Radiopharmaceuticals II-54

Devicor™ Medical Products Acquires Neoprobe® II-54

UHN and CPDC Form Joint Venture II-55

AstraZeneca Inks Licensing Agreement with Neoprobe II-55

Cardinal Health Unveils Molecular Imaging Collaboration Center in Phoenix Region II-56

11. CORPORATE ACTIVITY IN THE RECENT PAST – A PERSPECTIVE BUILDER II-57

Covidien Enters into Agreement with IAE POLATOM II-57

Dalat Nuclear Research Institute Inks Agreement with Probactive Biotech II-57

Principio Wins Licensing Agreement from Johns Hopkins Sidney Kimmel Comprehensive Cancer Center II-57

Covidien Inks Definitive Agreement with Triad Isotopes II-57

Eli Lilly Inks Merger Agreement with Avid Radiopharmaceuticals II-58

Lumiphore Inks Agreement with Algeta II-58

IBA Renews Contract with Servicio Andaluz de Salud II-58

Lumiphore and Algeta Ink Partnership Agreement II-59

Positron and Covidien Ink Agreement II-59

PETNET Solutions Expands PET Radiopharmaceutical Network II-60

Triad Isotopes Acquires Radiopharmacy Network of Covidien II-60

Principio Receives Exclusive Technological Development License

from Hopkins Sidney Kimmel Comprehensive Cancer Center II-60

PETNET Solutions Renews Supply Agreement with Paul Strickland Scanner Centre II-60

IBA Molecular Obtains Marketing Approval for Filtracis Radiopharmaceutical Kit II-61

DHA Inks MoU with DCD II-61

Algeta Signs Agreement with Bayer II-61

Antisoma Collaborates with Bryan Oncor II-61

Karpov Institute Enters into Collaboration with MDS Nordion II-62

MDS Nordion Establishes Glucotrace Facility II-62

Draximage Inks Agreement with Guerbet II-62

Eczacybathorny-Monrol Collaborates with IBA II-63

Siemens Healthcare Signs Agreement with Calypso Medical II-63

Molecular Insight Signs Agreement with BioMedica Life Sciences II-64

Bayer Schering Signs Agreement with Algeta II-64

IBA Inks Agreement with Aposense II-64

Draxis Receives Approval from Health Canada for Generic Sestamibi II-65

Cyclopharm and Alfred Health Solutions Form Joint Venture II-65

Guerbet Inks Distribution Agreement with Draximage II-65

Ion Beam Applications Collaborates with Eczacibasi-Monrol Nuclear Products II-66

12. FOCUS ON SELECT PLAYERS II-67

Actinium Pharmaceuticals Inc (US) II-67

Advanced Medical Isotope Corporation (US) II-67

Alseres Pharmaceuticals, Inc (US) II-67

Bayer HealthCare Pharmaceuticals Inc (US) II-68

Bracco Diagnostics, Inc. (US) II-68

Cardinal Health, Inc (US) II-69

Covidien Plc (Ireland) II-69

Eli Lilly and Company (US) II-70

Erigal Limited (UK) II-71

EUSA Pharma (Europe) Ltd. (UK) II-71

GE Healthcare (UK) II-72

IBA Group (Belgium) II-72

Immunomedics, Inc. (US) II-73

Jubilant Life Sciences Limited (India) II-73

Lantheus Medical Imaging Inc (US) II-74

Medi-Radiopharma Ltd (Hungary) II-74

Nordion Inc (Canada) II-75

Peregrine Pharmaceuticals, Inc. (US) II-75

PETNET Solutions Inc (US) II-76

Positron Corporation (US) II-76

Singapore Radiopharmaceuticals Pte Ltd (Singapore) II-77

Triad Isotopes, Inc. (US) II-77

13. GLOBAL MARKET PERSPECTIVE II-78

Table 13: World Recent Past, Current & Future Analysis for Radiopharmaceuticals by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific, Middle East and Latin American Markets Independently Analyzed with Annual Sales in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart) II-78

Table 14: World Historic Review for Radiopharmaceuticals by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific, Middle East and Latin American Markets Independently Analyzed

with Annual Sales in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart) II-79

Table 15: World 15-Year Perspective for Radiopharmaceuticals by Geographic Region – Percentage Breakdown of Value Sales for US, Canada, Japan, Europe, Asia-Pacific, Middle East and Latin American for 2005, 2013 & 2018 (includes corresponding Graph/Chart) II-80

Table 16: World Recent Past, Current & Future Analysis for Diagnostic Radiopharmaceuticals by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific, Middle East and Latin American Markets Independently Analyzed with Annual Sales in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart) II-81

Table 17: World Historic Review for Diagnostic Radiopharmaceuticals by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific, Middle East and Latin American Markets Independently Analyzed with Annual Sales in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart) II-82

Table 18: World 15-Year Perspective for Diagnostic Radiopharmaceuticals by Geographic Region – Percentage Breakdown of Value Sales for US, Canada, Japan, Europe, Asia-Pacific, Middle East and Latin American Markets for 2005, 2013 & 2018 (includes corresponding Graph/Chart) II-83

Table 19: World Recent Past, Current & Future Analysis for Therapeutic Radiopharmaceuticals by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific, Middle East and Latin

American Markets Independently Analyzed with Annual Sales in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart) II-84

Table 20: World Historic Review for Therapeutic Radiopharmaceuticals by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific, Middle East and Latin American Markets Independently Analyzed with Annual Sales in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart) II-85

Table 21: World 15-Year Perspective for Therapeutic Radiopharmaceuticals by Geographic Region – Percentage Breakdown of Value Sales for US, Canada, Japan, Europe,

Asia-Pacific, Middle East and Latin American Markets for 2005, 2013 & 2018 (includes corresponding Graph/Chart) II-86

III. MARKET

1. THE UNITED STATES III-1

A.Market Analysis III-1

Outlook III-1

Industry Structure III-1

Production Scenario III-1

Dependence on Imports III-1

DOE’s Flawed Isotope Program Causes Shortage Fears in the US III-2

Regulatory Scenario III-2

Thorny Regulations Dampen New Product Development III-2

FDA’s Antidote III-3

Overview of Medicare Reimbursements III-3

Medicare Payment Settings for Contrast Agents and

Radiopharmaceuticals III-4

Payments for Radiology Services III-4

Medicare Coverage III-4

Billing and Payment on Medicare Professional Claims III-4

Payment Conditions for Radiology Services III-4

Services Furnished in Hospitals to Inpatients III-5

Services Furnished in Hospitals to Outpatients III-5

Services Furnished in Skilled Nursing Facilities (SNF) III-5

Services Furnished by Rural Health Clinics (RHC) and

Federally Qualified Health Centers (FQHC) III-5

Implications of Reimbursement Changes on Radiology III-5

Radiopharmaceutical Reimbursement in the US: Who’s Under the

Umbrella III-6

Diagnostic Radiopharmaceuticals Bundled As Supplies under

Medicare Reimbursements III-6

Concerns over Bundling of Zevalin into Diagnostic

Radiopharmaceuticals Allayed III-6

Improved Reimbursement for Therapeutic Radiopharmaceuticals III-7

Market Overview III-7

Sanguine Growth On Cards III-7

Expanding Diagnostic Applications Will Stimulate Future Growth III-7

Nuclear Cardiology Products Drive Up Diagnostic

Radiopharmaceuticals Market III-7

Cardiovascular Imaging To Lead Volume Growth III-8

Cardiolite Loses Market Share to Generics III-8

Table 22: The US Diagnostic Radiopharmaceutical Agents Market (2012): Percentage Share Breakdown of Procedure Volume by Imaging Procedure – SPECT and PET (includes corresponding Graph/Chart) III-9

Table 23: US Market for Diagnostic Radiopharmaceuticals Agents (2012): Percentage Share Breakdown of Value Sales for Cardiology and Non-Cardiology Applications (includes corresponding Graph/Chart) III-9

Table 24: US Market for Cardiology Diagnostic Radiopharmaceuticals (2010): Percentage Share Breakdown of SPECT Myocardial Perfusion Imaging (MPI) Procedure Volume by Imaging Agent – Cardiolite, Myoview, Thallium, and Sestamibi (includes corresponding Graph/Chart) III-10

New Oncology, Neurology Agents to Boost Diagnostic Radiopharmaceuticals Market III-10

Table 25: US Market for Non-Cardiology Diagnostic Radiopharmaceuticals Agents (2012): Percentage Share Breakdown of Value Sales for Oncology and Non-Oncology

Applications (includes corresponding Graph/Chart) III-11

Installed Base of SPECT Scanners III-11

Table 26: Diagnostic Radiopharmaceutical Market in North America: Installed Base for SPECT and SPECT/CT Scanners in Units for Years 2006, 2008, 2010, 2012 & 2014 (includes

corresponding Graph/Chart) III-11

Installed Pet Scanners in US III-12

US FDG Market III-12

Table 27: US FDG Market (2012): Percentage Share Breakdown of Procedure Volume by Procedure Type – Oncology, Neurology and Cardiology (includes corresponding Graph/Chart) III-12

Focused R&D Efforts will Fuel Therapeutic Radiopharmaceuticals Market III-12

Market Share Statistics III-13

Table 28: US Market for Diagnostic Radiopharmaceuticals Agents (2011): Percentage Market Share Breakdown for Leading Players (includes corresponding Graph/Chart) III-13

Table 29: US Market for Therapeutic Radiopharmaceuticals (2012): Percentage Share Breakdown of Value Sales by Key Radiotherapeutics – Bone Palliation, Non-Hodgkin's Lymphoma, Hyperthyroidism /Thyroid Cancer and Others (includes corresponding Graph/Chart) III-13

Table 30: US Market for Therapeutic Radiopharmaceutical Agents (2010): Percentage Market Share Breakdown of Leading Players (includes corresponding Graph/Chart) III-14

Table 31: US Market for Radiopharmaceutical Bone Palliation Procedures (2012): Percentage Share Breakdown by Key Radiotherapeutics – Metastron, Quadramet and Sr-89

(includes corresponding Graph/Chart) III-14

Table 32: Radiopharmacy Market in the US (2012): Percentage Breakdown of Revenues Generated by General Radiopharmacies and FDG Radiopharmacies (includes corresponding Graph/Chart) III-14

Product Launches III-15

Strategic Corporate Developments III-15

Select Players III-19

B.Market Analytics III-28

Table 33: US Recent Past, Current & Future Analysis for Radiopharmaceuticals by Segment – Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals

Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart) III-28

Table 34: US Historic Review for Radiopharmaceuticals by Segment – Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart) III-29

Table 35: US 15-Year Perspective for Radiopharmaceuticals by Segment – Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets for Years 2005, 2013 & 2018 (includes corresponding Graph/Chart) III-30

2. CANADA III-31

A.Market Analysis III-31

Outlook III-31

Canadian Scientists Lead the Discovery of Remedy for Supply Shortages III-31

An Overview of Medical Imaging Market III-31

Regulatory and Legal Restrictions III-32

Strategic Corporate Developments III-32

Select Players III-33

B.Market Analytics III-35

Table 36: Canadian Recent Past, Current & Future Analysis for Radiopharmaceuticals by Segment – Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals

Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)

Read the full report:

Global Radiopharmaceuticals Industry

http://www.reportbuyer.com/pharma_healthcare/diagnostics/global_radiopharmaceuticals_industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging


For more information:

Sarah Smith

Research Advisor at Reportbuyer.com

Email: query@reportbuyer.com

Tel: +44 208 816 85 48

Website: http://www.reportbuyer.com

For the original version on PRWeb visit: http://www.prweb.com/releases/2013/9/prweb11156518.htm


Source: prweb



comments powered by Disqus